Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) FCF Margin: 2023-2025

Historic FCF Margin for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to -2,340.40%.

  • CG Oncology's FCF Margin rose 3467821.00% to -2,340.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -5,283.18%, marking a year-over-year increase of 534855.00%. This contributed to the annual value of -6,931.26% for FY2024, which is 1546041.00% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's FCF Margin is -2,340.40%, which was up 95.85% from -56,376.92% recorded in Q1 2025.
  • Over the past 5 years, CG Oncology's FCF Margin peaked at -2,340.40% during Q3 2025, and registered a low of -1,464,500.00% during Q4 2023.
  • For the 3-year period, CG Oncology's FCF Margin averaged around -191,625.38%, with its median value being -14,535.14% (2024).
  • Per our database at Business Quant, CG Oncology's FCF Margin spiked by 145,992,303bps in 2024 and then crashed by 5,145,745bps in 2025.
  • Over the past 3 years, CG Oncology's FCF Margin (Quarterly) stood at -1,464,500.00% in 2023, then surged by 145,992,303bps to -4,576.97% in 2024, then skyrocketed by 3,467,821bps to -2,340.40% in 2025.
  • Its FCF Margin was -2,340.40% in Q3 2025, compared to -56,376.92% in Q1 2025 and -4,576.97% in Q4 2024.